Belantamab mafodotin shows positive ORR in a recent DREAMM-2 study
Category: #health  By Mateen Dalal  Date: 2019-12-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Belantamab mafodotin shows positive ORR in a recent DREAMM-2 study

GlaxoSmithKline, a UK-based pharmaceutical company recently announced treatment of patients with heavily pre-treated multiple myeloma with belantamab mafodotin, an investigational agent. The study resulted in a clinically meaningful 31% ORR (overall response rate) with a 2.5 mg/kg regimen in the patients.

For the record, Multiple myeloma is one of the most common blood cancers, which is usually considered treatable, but not curable. The disease commonly becomes relapsed/refractory to available treatments, prompting the need for research into new therapies for potential treatment.

The complete result from the pivotal study DREAMM-2 (DRiving Excellence in Approaches to Multiple Myeloma) of belantamab mafodotin (GSK2857916) was published recently in The Lancet Oncology. GlaxoSmithKline has also confirmed the submission of a Biologics License Application to the US FDA, seeking approval of the investigational for the treatment of patients with refractory/relapsed multiple myeloma, which were earlier treated with an anti-CD38 antibody, an immunomodulatory agent and a proteasome. Currently, Belantamab mafodotin is not  approved for use anywhere in the world.

As observed in a set of patients in the DREAMM-1 study, the results demonstrated in DREAMM-2 were also consistent. Based on the data, GlaxoSmithKline is expected to seek approval of the 2.5 mg/kg dose.  If the submission is approved, belantamab mafodotin will become the first anti-BCMA (B-cell maturation antigen) agent available in the US.

In the study, 30 of the 97 patients in the 2.5 mg/kg cohort achieved an ORR. Out of these, 18 patients attained a very good partial response, including three patients with a complete response.

Dr Hal Barron, CSO and President Research & Development, GlaxoSmithKline was reportedly quoted saying that patients with multiple myeloma whose disease has progressed negatively despite the currently available therapies, are left with limited options. The data from the recent study shows that, if approved, the investigational belantamab mafodotin is likely to offer a significant new treatment option for these patients.

Source Credits: https://www.gsk.com/en-gb/media/press-releases/pivotal-dreamm-2-study-demonstrated-a-clinically-meaningful-overall-response-rate-with-belantamab-mafodotin-gsk2857916-for-patients-with-relapsedrefractory-multiple-myeloma/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

PayPal buys Happy Returns to strengthen reverse logistics system
PayPal buys Happy Returns to strengthen reverse logistics system
By Mateen Dalal

U.S. based digital payments platform, PayPal, an online payment system entity has announced the purchase of Happy Returns- a returns solution firm that provides online buyers access to simplified ways to return unwanted merchandise to retailers; elim...

YOP officially unveils YOP app to ease access to DeFi for the masses
YOP officially unveils YOP app to ease access to DeFi for the masses
By Mateen Dalal

Yield Optimization Platform and Protocol (YOP) recently declared its official launch of YOP application; the first all-in-one mobile app which makes it quite easier for everyone to access DeFi. The V0 version of the app is now available for early acc...

Singapore to create second national supercomputer with more on roadmap
Singapore to create second national supercomputer with more on roadmap
By Mateen Dalal

Following its success of the first supercomputer system, Singapore is set to build its upcoming second supercomputer system in an attempt to strengthen the local research community, offering 8X more computing capacity than its previous model. The sy...